nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—Fludarabine—lymphatic system cancer	0.361	1	CrCtD
Cladribine—POLE—Cytarabine—lymphatic system cancer	0.0588	0.183	CbGbCtD
Cladribine—RRM1—Fludarabine—lymphatic system cancer	0.0573	0.178	CbGbCtD
Cladribine—SLC28A3—Fludarabine—lymphatic system cancer	0.0495	0.154	CbGbCtD
Cladribine—POLA1—Fludarabine—lymphatic system cancer	0.0495	0.154	CbGbCtD
Cladribine—POLA1—Cytarabine—lymphatic system cancer	0.0338	0.105	CbGbCtD
Cladribine—DCK—Fludarabine—lymphatic system cancer	0.0305	0.0946	CbGbCtD
Cladribine—DCK—Cytarabine—lymphatic system cancer	0.0208	0.0646	CbGbCtD
Cladribine—Clofarabine—Fludarabine—lymphatic system cancer	0.0195	0.0737	CrCrCtD
Cladribine—Regadenoson—Fludarabine—lymphatic system cancer	0.0195	0.0737	CrCrCtD
Cladribine—Clofarabine—Cytarabine—lymphatic system cancer	0.0184	0.0696	CrCrCtD
Cladribine—Regadenoson—Cytarabine—lymphatic system cancer	0.0184	0.0696	CrCrCtD
Cladribine—Fludarabine—Cytarabine—lymphatic system cancer	0.0173	0.0653	CrCrCtD
Cladribine—Nelarabine—Fludarabine—lymphatic system cancer	0.0172	0.0652	CrCrCtD
Cladribine—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0172	0.0652	CrCrCtD
Cladribine—Nelarabine—Cytarabine—lymphatic system cancer	0.0163	0.0616	CrCrCtD
Cladribine—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0163	0.0616	CrCrCtD
Cladribine—Adenosine—Fludarabine—lymphatic system cancer	0.0155	0.0586	CrCrCtD
Cladribine—Azacitidine—Fludarabine—lymphatic system cancer	0.0155	0.0586	CrCrCtD
Cladribine—Vidarabine—Fludarabine—lymphatic system cancer	0.0155	0.0586	CrCrCtD
Cladribine—Vidarabine—Cytarabine—lymphatic system cancer	0.0146	0.0553	CrCrCtD
Cladribine—Adenosine—Cytarabine—lymphatic system cancer	0.0146	0.0553	CrCrCtD
Cladribine—Azacitidine—Cytarabine—lymphatic system cancer	0.0146	0.0553	CrCrCtD
Cladribine—Decitabine—Cytarabine—lymphatic system cancer	0.0139	0.0527	CrCrCtD
Cladribine—SLC22A2—Cytarabine—lymphatic system cancer	0.006	0.0186	CbGbCtD
Cladribine—SLC22A1—Cytarabine—lymphatic system cancer	0.00521	0.0162	CbGbCtD
Cladribine—ABCG2—Teniposide—lymphatic system cancer	0.00436	0.0135	CbGbCtD
Cladribine—ABCG2—Mitoxantrone—lymphatic system cancer	0.00305	0.00948	CbGbCtD
Cladribine—ABCG2—Vincristine—lymphatic system cancer	0.0021	0.00652	CbGbCtD
Cladribine—ABCG2—Methotrexate—lymphatic system cancer	0.00127	0.00395	CbGbCtD
Cladribine—RRM2—Vinorelbine—Vincristine—lymphatic system cancer	0.000231	0.195	CbGdCrCtD
Cladribine—POLA1—Vinblastine—Vincristine—lymphatic system cancer	0.000218	0.184	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Fludarabine—lymphatic system cancer	0.000157	0.132	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Cytarabine—lymphatic system cancer	0.000148	0.125	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Fludarabine—lymphatic system cancer	0.000124	0.104	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Cytarabine—lymphatic system cancer	0.000117	0.0987	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Fludarabine—lymphatic system cancer	9.84e-05	0.083	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Cytarabine—lymphatic system cancer	9.29e-05	0.0784	CbGdCrCtD
Cladribine—Haemorrhage—Mitoxantrone—lymphatic system cancer	5.97e-05	0.00115	CcSEcCtD
Cladribine—Ill-defined disorder—Bleomycin—lymphatic system cancer	5.94e-05	0.00114	CcSEcCtD
Cladribine—Pharyngitis—Mitoxantrone—lymphatic system cancer	5.93e-05	0.00114	CcSEcCtD
Cladribine—Pulmonary embolism—Methotrexate—lymphatic system cancer	5.92e-05	0.00114	CcSEcCtD
Cladribine—Anaemia—Bleomycin—lymphatic system cancer	5.92e-05	0.00114	CcSEcCtD
Cladribine—Feeling abnormal—Fludarabine—lymphatic system cancer	5.88e-05	0.00113	CcSEcCtD
Cladribine—Asthenia—Teniposide—lymphatic system cancer	5.82e-05	0.00112	CcSEcCtD
Cladribine—Malaise—Bleomycin—lymphatic system cancer	5.78e-05	0.00111	CcSEcCtD
Cladribine—Pruritus—Teniposide—lymphatic system cancer	5.74e-05	0.0011	CcSEcCtD
Cladribine—Arrhythmia—Carmustine—lymphatic system cancer	5.74e-05	0.0011	CcSEcCtD
Cladribine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	5.72e-05	0.0011	CcSEcCtD
Cladribine—Cardiac disorder—Vincristine—lymphatic system cancer	5.69e-05	0.00109	CcSEcCtD
Cladribine—Alopecia—Carmustine—lymphatic system cancer	5.68e-05	0.00109	CcSEcCtD
Cladribine—Body temperature increased—Fludarabine—lymphatic system cancer	5.64e-05	0.00108	CcSEcCtD
Cladribine—Mental disorder—Carmustine—lymphatic system cancer	5.63e-05	0.00108	CcSEcCtD
Cladribine—Erythema—Carmustine—lymphatic system cancer	5.59e-05	0.00108	CcSEcCtD
Cladribine—Malnutrition—Carmustine—lymphatic system cancer	5.59e-05	0.00108	CcSEcCtD
Cladribine—Cough—Bleomycin—lymphatic system cancer	5.59e-05	0.00108	CcSEcCtD
Cladribine—Angiopathy—Vincristine—lymphatic system cancer	5.56e-05	0.00107	CcSEcCtD
Cladribine—Aplastic anaemia—Methotrexate—lymphatic system cancer	5.56e-05	0.00107	CcSEcCtD
Cladribine—Diarrhoea—Teniposide—lymphatic system cancer	5.55e-05	0.00107	CcSEcCtD
Cladribine—Mediastinal disorder—Vincristine—lymphatic system cancer	5.53e-05	0.00106	CcSEcCtD
Cladribine—Myalgia—Bleomycin—lymphatic system cancer	5.45e-05	0.00105	CcSEcCtD
Cladribine—Chest pain—Bleomycin—lymphatic system cancer	5.45e-05	0.00105	CcSEcCtD
Cladribine—Alopecia—Vincristine—lymphatic system cancer	5.42e-05	0.00104	CcSEcCtD
Cladribine—Back pain—Carmustine—lymphatic system cancer	5.41e-05	0.00104	CcSEcCtD
Cladribine—Discomfort—Bleomycin—lymphatic system cancer	5.39e-05	0.00104	CcSEcCtD
Cladribine—Mental disorder—Vincristine—lymphatic system cancer	5.37e-05	0.00103	CcSEcCtD
Cladribine—Chills—Mitoxantrone—lymphatic system cancer	5.36e-05	0.00103	CcSEcCtD
Cladribine—Ecchymosis—Methotrexate—lymphatic system cancer	5.36e-05	0.00103	CcSEcCtD
Cladribine—Neoplasm—Methotrexate—lymphatic system cancer	5.36e-05	0.00103	CcSEcCtD
Cladribine—Arrhythmia—Mitoxantrone—lymphatic system cancer	5.33e-05	0.00103	CcSEcCtD
Cladribine—Alopecia—Mitoxantrone—lymphatic system cancer	5.28e-05	0.00102	CcSEcCtD
Cladribine—Confusional state—Bleomycin—lymphatic system cancer	5.27e-05	0.00101	CcSEcCtD
Cladribine—Hypersensitivity—Fludarabine—lymphatic system cancer	5.25e-05	0.00101	CcSEcCtD
Cladribine—Oedema—Bleomycin—lymphatic system cancer	5.23e-05	0.00101	CcSEcCtD
Cladribine—Erythema—Mitoxantrone—lymphatic system cancer	5.2e-05	0.001	CcSEcCtD
Cladribine—Infection—Bleomycin—lymphatic system cancer	5.19e-05	0.000999	CcSEcCtD
Cladribine—Anaemia—Carmustine—lymphatic system cancer	5.17e-05	0.000994	CcSEcCtD
Cladribine—Back pain—Vincristine—lymphatic system cancer	5.16e-05	0.000993	CcSEcCtD
Cladribine—Vomiting—Teniposide—lymphatic system cancer	5.16e-05	0.000992	CcSEcCtD
Cladribine—Sepsis—Methotrexate—lymphatic system cancer	5.14e-05	0.000989	CcSEcCtD
Cladribine—Thrombocytopenia—Bleomycin—lymphatic system cancer	5.12e-05	0.000985	CcSEcCtD
Cladribine—Asthenia—Fludarabine—lymphatic system cancer	5.12e-05	0.000984	CcSEcCtD
Cladribine—Rash—Teniposide—lymphatic system cancer	5.12e-05	0.000984	CcSEcCtD
Cladribine—Dermatitis—Teniposide—lymphatic system cancer	5.11e-05	0.000983	CcSEcCtD
Cladribine—Headache—Teniposide—lymphatic system cancer	5.08e-05	0.000978	CcSEcCtD
Cladribine—Pruritus—Fludarabine—lymphatic system cancer	5.04e-05	0.00097	CcSEcCtD
Cladribine—Back pain—Mitoxantrone—lymphatic system cancer	5.03e-05	0.000967	CcSEcCtD
Cladribine—Anorexia—Bleomycin—lymphatic system cancer	4.98e-05	0.000959	CcSEcCtD
Cladribine—Anaemia—Vincristine—lymphatic system cancer	4.93e-05	0.000949	CcSEcCtD
Cladribine—Hypotension—Bleomycin—lymphatic system cancer	4.89e-05	0.00094	CcSEcCtD
Cladribine—Diarrhoea—Fludarabine—lymphatic system cancer	4.88e-05	0.000938	CcSEcCtD
Cladribine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	4.82e-05	0.000928	CcSEcCtD
Cladribine—Nausea—Teniposide—lymphatic system cancer	4.82e-05	0.000927	CcSEcCtD
Cladribine—Anaemia—Mitoxantrone—lymphatic system cancer	4.8e-05	0.000924	CcSEcCtD
Cladribine—Hepatic failure—Methotrexate—lymphatic system cancer	4.79e-05	0.000921	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	4.76e-05	0.000916	CcSEcCtD
Cladribine—Chest pain—Carmustine—lymphatic system cancer	4.76e-05	0.000916	CcSEcCtD
Cladribine—Myalgia—Carmustine—lymphatic system cancer	4.76e-05	0.000916	CcSEcCtD
Cladribine—Anxiety—Carmustine—lymphatic system cancer	4.74e-05	0.000913	CcSEcCtD
Cladribine—Paraesthesia—Bleomycin—lymphatic system cancer	4.69e-05	0.000903	CcSEcCtD
Cladribine—Malaise—Mitoxantrone—lymphatic system cancer	4.69e-05	0.000902	CcSEcCtD
Cladribine—Dyspnoea—Bleomycin—lymphatic system cancer	4.66e-05	0.000897	CcSEcCtD
Cladribine—Renal failure acute—Methotrexate—lymphatic system cancer	4.66e-05	0.000896	CcSEcCtD
Cladribine—Confusional state—Carmustine—lymphatic system cancer	4.6e-05	0.000885	CcSEcCtD
Cladribine—Oedema—Carmustine—lymphatic system cancer	4.56e-05	0.000878	CcSEcCtD
Cladribine—Decreased appetite—Bleomycin—lymphatic system cancer	4.54e-05	0.000874	CcSEcCtD
Cladribine—Myalgia—Vincristine—lymphatic system cancer	4.54e-05	0.000874	CcSEcCtD
Cladribine—Cough—Mitoxantrone—lymphatic system cancer	4.54e-05	0.000873	CcSEcCtD
Cladribine—Infection—Carmustine—lymphatic system cancer	4.53e-05	0.000872	CcSEcCtD
Cladribine—Vomiting—Fludarabine—lymphatic system cancer	4.53e-05	0.000872	CcSEcCtD
Cladribine—Rash—Fludarabine—lymphatic system cancer	4.5e-05	0.000865	CcSEcCtD
Cladribine—Dermatitis—Fludarabine—lymphatic system cancer	4.49e-05	0.000864	CcSEcCtD
Cladribine—Pain—Bleomycin—lymphatic system cancer	4.47e-05	0.00086	CcSEcCtD
Cladribine—Thrombocytopenia—Carmustine—lymphatic system cancer	4.47e-05	0.000859	CcSEcCtD
Cladribine—Headache—Fludarabine—lymphatic system cancer	4.47e-05	0.000859	CcSEcCtD
Cladribine—Tachycardia—Carmustine—lymphatic system cancer	4.45e-05	0.000857	CcSEcCtD
Cladribine—Myalgia—Mitoxantrone—lymphatic system cancer	4.43e-05	0.000851	CcSEcCtD
Cladribine—Chest pain—Mitoxantrone—lymphatic system cancer	4.43e-05	0.000851	CcSEcCtD
Cladribine—Arthralgia—Mitoxantrone—lymphatic system cancer	4.43e-05	0.000851	CcSEcCtD
Cladribine—Anxiety—Mitoxantrone—lymphatic system cancer	4.41e-05	0.000848	CcSEcCtD
Cladribine—Lethargy—Methotrexate—lymphatic system cancer	4.39e-05	0.000844	CcSEcCtD
Cladribine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	4.39e-05	0.000844	CcSEcCtD
Cladribine—Discomfort—Mitoxantrone—lymphatic system cancer	4.37e-05	0.000841	CcSEcCtD
Cladribine—Oedema—Vincristine—lymphatic system cancer	4.36e-05	0.000838	CcSEcCtD
Cladribine—Anorexia—Carmustine—lymphatic system cancer	4.35e-05	0.000837	CcSEcCtD
Cladribine—Infection—Vincristine—lymphatic system cancer	4.33e-05	0.000832	CcSEcCtD
Cladribine—Feeling abnormal—Bleomycin—lymphatic system cancer	4.31e-05	0.000829	CcSEcCtD
Cladribine—Confusional state—Mitoxantrone—lymphatic system cancer	4.28e-05	0.000823	CcSEcCtD
Cladribine—Nervous system disorder—Vincristine—lymphatic system cancer	4.27e-05	0.000822	CcSEcCtD
Cladribine—Thrombocytopenia—Vincristine—lymphatic system cancer	4.27e-05	0.00082	CcSEcCtD
Cladribine—Hypotension—Carmustine—lymphatic system cancer	4.26e-05	0.00082	CcSEcCtD
Cladribine—Oedema—Mitoxantrone—lymphatic system cancer	4.24e-05	0.000816	CcSEcCtD
Cladribine—Nausea—Fludarabine—lymphatic system cancer	4.24e-05	0.000815	CcSEcCtD
Cladribine—Infection—Mitoxantrone—lymphatic system cancer	4.21e-05	0.000811	CcSEcCtD
Cladribine—Hyperhidrosis—Vincristine—lymphatic system cancer	4.21e-05	0.00081	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	4.16e-05	0.0008	CcSEcCtD
Cladribine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	4.15e-05	0.000799	CcSEcCtD
Cladribine—Urticaria—Bleomycin—lymphatic system cancer	4.15e-05	0.000799	CcSEcCtD
Cladribine—Anorexia—Vincristine—lymphatic system cancer	4.15e-05	0.000799	CcSEcCtD
Cladribine—Tachycardia—Mitoxantrone—lymphatic system cancer	4.14e-05	0.000796	CcSEcCtD
Cladribine—Body temperature increased—Bleomycin—lymphatic system cancer	4.13e-05	0.000795	CcSEcCtD
Cladribine—Insomnia—Carmustine—lymphatic system cancer	4.13e-05	0.000794	CcSEcCtD
Cladribine—Skin disorder—Mitoxantrone—lymphatic system cancer	4.12e-05	0.000793	CcSEcCtD
Cladribine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	4.1e-05	0.000789	CcSEcCtD
Cladribine—Paraesthesia—Carmustine—lymphatic system cancer	4.1e-05	0.000788	CcSEcCtD
Cladribine—Hypotension—Vincristine—lymphatic system cancer	4.07e-05	0.000783	CcSEcCtD
Cladribine—Dyspnoea—Carmustine—lymphatic system cancer	4.07e-05	0.000783	CcSEcCtD
Cladribine—Somnolence—Carmustine—lymphatic system cancer	4.06e-05	0.00078	CcSEcCtD
Cladribine—Anorexia—Mitoxantrone—lymphatic system cancer	4.04e-05	0.000778	CcSEcCtD
Cladribine—Ataxia—Methotrexate—lymphatic system cancer	4.04e-05	0.000778	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.97e-05	0.000763	CcSEcCtD
Cladribine—Decreased appetite—Carmustine—lymphatic system cancer	3.97e-05	0.000763	CcSEcCtD
Cladribine—Hypotension—Mitoxantrone—lymphatic system cancer	3.96e-05	0.000763	CcSEcCtD
Cladribine—Insomnia—Vincristine—lymphatic system cancer	3.94e-05	0.000758	CcSEcCtD
Cladribine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.94e-05	0.000758	CcSEcCtD
Cladribine—Paraesthesia—Vincristine—lymphatic system cancer	3.91e-05	0.000752	CcSEcCtD
Cladribine—Pain—Carmustine—lymphatic system cancer	3.9e-05	0.000751	CcSEcCtD
Cladribine—Constipation—Carmustine—lymphatic system cancer	3.9e-05	0.000751	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.87e-05	0.000745	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.87e-05	0.000743	CcSEcCtD
Cladribine—Hypersensitivity—Bleomycin—lymphatic system cancer	3.85e-05	0.000741	CcSEcCtD
Cladribine—Paraesthesia—Mitoxantrone—lymphatic system cancer	3.81e-05	0.000733	CcSEcCtD
Cladribine—Decreased appetite—Vincristine—lymphatic system cancer	3.79e-05	0.000728	CcSEcCtD
Cladribine—Dyspnoea—Mitoxantrone—lymphatic system cancer	3.78e-05	0.000728	CcSEcCtD
Cladribine—Somnolence—Mitoxantrone—lymphatic system cancer	3.77e-05	0.000725	CcSEcCtD
Cladribine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	3.76e-05	0.000723	CcSEcCtD
Cladribine—Feeling abnormal—Carmustine—lymphatic system cancer	3.76e-05	0.000723	CcSEcCtD
Cladribine—Fatigue—Vincristine—lymphatic system cancer	3.76e-05	0.000722	CcSEcCtD
Cladribine—Asthenia—Bleomycin—lymphatic system cancer	3.75e-05	0.000722	CcSEcCtD
Cladribine—Gastrointestinal pain—Carmustine—lymphatic system cancer	3.73e-05	0.000718	CcSEcCtD
Cladribine—Pain—Vincristine—lymphatic system cancer	3.73e-05	0.000717	CcSEcCtD
Cladribine—Constipation—Vincristine—lymphatic system cancer	3.73e-05	0.000717	CcSEcCtD
Cladribine—Pruritus—Bleomycin—lymphatic system cancer	3.7e-05	0.000711	CcSEcCtD
Cladribine—Decreased appetite—Mitoxantrone—lymphatic system cancer	3.69e-05	0.000709	CcSEcCtD
Cladribine—Eosinophilia—Methotrexate—lymphatic system cancer	3.68e-05	0.000708	CcSEcCtD
Cladribine—Fatigue—Mitoxantrone—lymphatic system cancer	3.66e-05	0.000704	CcSEcCtD
Cladribine—Constipation—Mitoxantrone—lymphatic system cancer	3.63e-05	0.000698	CcSEcCtD
Cladribine—Pain—Mitoxantrone—lymphatic system cancer	3.63e-05	0.000698	CcSEcCtD
Cladribine—Abdominal pain—Carmustine—lymphatic system cancer	3.61e-05	0.000694	CcSEcCtD
Cladribine—Body temperature increased—Carmustine—lymphatic system cancer	3.61e-05	0.000694	CcSEcCtD
Cladribine—Abdominal discomfort—Methotrexate—lymphatic system cancer	3.56e-05	0.000685	CcSEcCtD
Cladribine—Gastrointestinal pain—Vincristine—lymphatic system cancer	3.56e-05	0.000685	CcSEcCtD
Cladribine—Pancytopenia—Methotrexate—lymphatic system cancer	3.53e-05	0.000679	CcSEcCtD
Cladribine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	3.5e-05	0.000672	CcSEcCtD
Cladribine—Neutropenia—Methotrexate—lymphatic system cancer	3.48e-05	0.000669	CcSEcCtD
Cladribine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000667	CcSEcCtD
Cladribine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	3.45e-05	0.000665	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—lymphatic system cancer	3.44e-05	0.000662	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—lymphatic system cancer	3.44e-05	0.000662	CcSEcCtD
Cladribine—Urticaria—Mitoxantrone—lymphatic system cancer	3.37e-05	0.000648	CcSEcCtD
Cladribine—Hypersensitivity—Carmustine—lymphatic system cancer	3.36e-05	0.000647	CcSEcCtD
Cladribine—Abdominal pain—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000645	CcSEcCtD
Cladribine—Body temperature increased—Mitoxantrone—lymphatic system cancer	3.35e-05	0.000645	CcSEcCtD
Cladribine—Pneumonia—Methotrexate—lymphatic system cancer	3.33e-05	0.000641	CcSEcCtD
Cladribine—Vomiting—Bleomycin—lymphatic system cancer	3.32e-05	0.000639	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—lymphatic system cancer	3.31e-05	0.000637	CcSEcCtD
Cladribine—Infestation—Methotrexate—lymphatic system cancer	3.31e-05	0.000637	CcSEcCtD
Cladribine—Rash—Bleomycin—lymphatic system cancer	3.3e-05	0.000634	CcSEcCtD
Cladribine—Dermatitis—Bleomycin—lymphatic system cancer	3.29e-05	0.000633	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	3.29e-05	0.000632	CcSEcCtD
Cladribine—Asthenia—Carmustine—lymphatic system cancer	3.27e-05	0.00063	CcSEcCtD
Cladribine—Renal failure—Methotrexate—lymphatic system cancer	3.26e-05	0.000627	CcSEcCtD
Cladribine—Conjunctivitis—Methotrexate—lymphatic system cancer	3.22e-05	0.00062	CcSEcCtD
Cladribine—Hypersensitivity—Vincristine—lymphatic system cancer	3.21e-05	0.000617	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	3.13e-05	0.000603	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—lymphatic system cancer	3.13e-05	0.000601	CcSEcCtD
Cladribine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	3.13e-05	0.000601	CcSEcCtD
Cladribine—Asthenia—Vincristine—lymphatic system cancer	3.13e-05	0.000601	CcSEcCtD
Cladribine—Diarrhoea—Carmustine—lymphatic system cancer	3.12e-05	0.000601	CcSEcCtD
Cladribine—Nausea—Bleomycin—lymphatic system cancer	3.11e-05	0.000597	CcSEcCtD
Cladribine—Asthenia—Mitoxantrone—lymphatic system cancer	3.04e-05	0.000586	CcSEcCtD
Cladribine—Dizziness—Carmustine—lymphatic system cancer	3.02e-05	0.00058	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—lymphatic system cancer	2.99e-05	0.000575	CcSEcCtD
Cladribine—Diarrhoea—Vincristine—lymphatic system cancer	2.98e-05	0.000573	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—lymphatic system cancer	2.98e-05	0.000572	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—lymphatic system cancer	2.95e-05	0.000568	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.94e-05	0.000565	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—lymphatic system cancer	2.92e-05	0.000561	CcSEcCtD
Cladribine—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.9e-05	0.000558	CcSEcCtD
Cladribine—Vomiting—Carmustine—lymphatic system cancer	2.9e-05	0.000558	CcSEcCtD
Cladribine—Dizziness—Vincristine—lymphatic system cancer	2.88e-05	0.000554	CcSEcCtD
Cladribine—Rash—Carmustine—lymphatic system cancer	2.88e-05	0.000553	CcSEcCtD
Cladribine—Dermatitis—Carmustine—lymphatic system cancer	2.87e-05	0.000553	CcSEcCtD
Cladribine—Headache—Carmustine—lymphatic system cancer	2.86e-05	0.00055	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—lymphatic system cancer	2.81e-05	0.000541	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—lymphatic system cancer	2.78e-05	0.000535	CcSEcCtD
Cladribine—Vomiting—Vincristine—lymphatic system cancer	2.77e-05	0.000533	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—lymphatic system cancer	2.76e-05	0.000531	CcSEcCtD
Cladribine—Rash—Vincristine—lymphatic system cancer	2.75e-05	0.000528	CcSEcCtD
Cladribine—Dermatitis—Vincristine—lymphatic system cancer	2.74e-05	0.000528	CcSEcCtD
Cladribine—Headache—Vincristine—lymphatic system cancer	2.73e-05	0.000525	CcSEcCtD
Cladribine—Nausea—Carmustine—lymphatic system cancer	2.71e-05	0.000521	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—lymphatic system cancer	2.7e-05	0.000519	CcSEcCtD
Cladribine—Vomiting—Mitoxantrone—lymphatic system cancer	2.7e-05	0.000519	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—lymphatic system cancer	2.69e-05	0.000517	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.68e-05	0.000516	CcSEcCtD
Cladribine—Rash—Mitoxantrone—lymphatic system cancer	2.67e-05	0.000515	CcSEcCtD
Cladribine—Dermatitis—Mitoxantrone—lymphatic system cancer	2.67e-05	0.000514	CcSEcCtD
Cladribine—Chills—Methotrexate—lymphatic system cancer	2.67e-05	0.000513	CcSEcCtD
Cladribine—Headache—Mitoxantrone—lymphatic system cancer	2.66e-05	0.000511	CcSEcCtD
Cladribine—Alopecia—Methotrexate—lymphatic system cancer	2.63e-05	0.000506	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—lymphatic system cancer	2.61e-05	0.000501	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—lymphatic system cancer	2.59e-05	0.000498	CcSEcCtD
Cladribine—Erythema—Methotrexate—lymphatic system cancer	2.59e-05	0.000498	CcSEcCtD
Cladribine—Nausea—Vincristine—lymphatic system cancer	2.59e-05	0.000498	CcSEcCtD
Cladribine—Nausea—Mitoxantrone—lymphatic system cancer	2.52e-05	0.000485	CcSEcCtD
Cladribine—Back pain—Methotrexate—lymphatic system cancer	2.51e-05	0.000482	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.4e-05	0.000462	CcSEcCtD
Cladribine—Anaemia—Methotrexate—lymphatic system cancer	2.39e-05	0.00046	CcSEcCtD
Cladribine—Malaise—Methotrexate—lymphatic system cancer	2.34e-05	0.000449	CcSEcCtD
Cladribine—Cough—Methotrexate—lymphatic system cancer	2.26e-05	0.000435	CcSEcCtD
Cladribine—Chest pain—Methotrexate—lymphatic system cancer	2.2e-05	0.000424	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—lymphatic system cancer	2.2e-05	0.000424	CcSEcCtD
Cladribine—Myalgia—Methotrexate—lymphatic system cancer	2.2e-05	0.000424	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	2.19e-05	0.000421	CcSEcCtD
Cladribine—Discomfort—Methotrexate—lymphatic system cancer	2.18e-05	0.000419	CcSEcCtD
Cladribine—Confusional state—Methotrexate—lymphatic system cancer	2.13e-05	0.00041	CcSEcCtD
Cladribine—Infection—Methotrexate—lymphatic system cancer	2.1e-05	0.000404	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—lymphatic system cancer	2.07e-05	0.000399	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.07e-05	0.000398	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—lymphatic system cancer	2.05e-05	0.000395	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.04e-05	0.000393	CcSEcCtD
Cladribine—Anorexia—Methotrexate—lymphatic system cancer	2.01e-05	0.000388	CcSEcCtD
Cladribine—Hypotension—Methotrexate—lymphatic system cancer	1.98e-05	0.00038	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.93e-05	0.00037	CcSEcCtD
Cladribine—Insomnia—Methotrexate—lymphatic system cancer	1.91e-05	0.000368	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—lymphatic system cancer	1.9e-05	0.000365	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—lymphatic system cancer	1.88e-05	0.000362	CcSEcCtD
Cladribine—Somnolence—Methotrexate—lymphatic system cancer	1.88e-05	0.000361	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—lymphatic system cancer	1.84e-05	0.000353	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.82e-05	0.000351	CcSEcCtD
Cladribine—Fatigue—Methotrexate—lymphatic system cancer	1.82e-05	0.000351	CcSEcCtD
Cladribine—Pain—Methotrexate—lymphatic system cancer	1.81e-05	0.000348	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.74e-05	0.000335	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.73e-05	0.000332	CcSEcCtD
Cladribine—Urticaria—Methotrexate—lymphatic system cancer	1.68e-05	0.000323	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—lymphatic system cancer	1.67e-05	0.000321	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—lymphatic system cancer	1.67e-05	0.000321	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—lymphatic system cancer	1.56e-05	0.0003	CcSEcCtD
Cladribine—Asthenia—Methotrexate—lymphatic system cancer	1.52e-05	0.000292	CcSEcCtD
Cladribine—Pruritus—Methotrexate—lymphatic system cancer	1.5e-05	0.000288	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—lymphatic system cancer	1.45e-05	0.000278	CcSEcCtD
Cladribine—Dizziness—Methotrexate—lymphatic system cancer	1.4e-05	0.000269	CcSEcCtD
Cladribine—Vomiting—Methotrexate—lymphatic system cancer	1.34e-05	0.000259	CcSEcCtD
Cladribine—Rash—Methotrexate—lymphatic system cancer	1.33e-05	0.000256	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—lymphatic system cancer	1.33e-05	0.000256	CcSEcCtD
Cladribine—Headache—Methotrexate—lymphatic system cancer	1.32e-05	0.000255	CcSEcCtD
Cladribine—Nausea—Methotrexate—lymphatic system cancer	1.26e-05	0.000242	CcSEcCtD
